A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas-Reference-Cited by-同舟云学术

A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas

Published:2021-08-02 Issue:14 Volume:62 Page:3493-3500
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Pearse William B.¹^ORCID,Petrich Adam M.¹,Gordon Leo I.¹,Karmali Reem¹,Winter Jane N.¹,Ma Shuo¹,Kaplan Jason B.¹^ORCID,Behdad Amir²,Klein Andreas³,Jovanovic Borko⁴,Helenowski Irene⁴,Smith Sonali M.⁵,Evens Andrew M.⁶,Pro Barbara¹

Affiliation:

1. Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

2. Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

3. Department of Hematology/Oncology, Tufts Medical Center, Boston, MA, USA

4. Department of Preventive Medicine, Northwestern University, Chicago, IL, USA

5. Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA

6. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1957867

Reference17 articles.

1. The role of immunosuppression in lymphoma formation

2. Swerdlow SH, Campo, E, Harris NL (editors). WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017. pp. 453–462.

3. A Defective, Rearranged Epstein-Barr Virus Genome in EBER-Negative and EBER-Positive Hodgkin's Disease

4. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease

5. Soluble CD30: A serum marker for Epstein-Barr virus-associated lymphoproliferative diseases

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of PTLD: a slow and difficult path;Blood;2024-07-25

2. Post-transplant lymphoproliferative disorders following kidney transplantation: A literature review with updates on risk factors, prognostic indices, screening strategies, treatment and analysis of donor type;Transplantation Reviews;2024-04

3. Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management;Blood Reviews;2024-03

4. A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter’s Transformation;Case Reports in Hematology;2024-02-24

5. Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21